TNBC represents a significant clinical challenge in the landscape of breast cancer due to its unique molecular profile characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression [4,5]. The gene discussed is ESR1; the disease is breast carcinoma.